Latest Advances

 

Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.

Treatment Used: Guselkumab
Number of Patients: 1
MediFind Summary

Overview: This case report discusses experience with a 58-year-old woman with Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders, who developed psoriasis and was treated with guselkumab.

Conclusion: Excellent, significant improvements were observed after only 3 months of guselkumab treatment, without adverse effects in a patient with Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders, and psoriasis.

Abstract

Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.

Authors
Cristina Mugheddu, Massimo Dell'antonia, Silvia Sanna, Daniele Agosta, Laura Atzori, Franco Rongioletti

View Article From Source